Welcome Back |Sign in | Register
Your Position: Home > Biology > Active small molecul > Ruxolitinib

View History

prev zoom next


  • Catalog No.:
  • BCM006383
  • Chem Name:
  • Ruxolitinib
  • Synonym:
  • (R)-3-(4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile;(betaR)-beta-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile;(3R)-3-(4-(7H-pyrrolo[2,3-d]pyriMidin-4-yl)-1H-pyrazol-1-yl)-3-Chemicalbookcyclopentylpropanenitrile;(3R)-3-cyclopentyl-3-(4-{7H-pyrrolo[2,3-d]pyriMidin-4-yl}-1H-pyrazol-1-yl)propanenitrile;INCB018424(Ruxolitinib);Jakafi;Roxolitinib;β-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyriMidin-4-yl)-(βR)-1H-pyrazole-1-propanenitrile
  • CAS No.:
  • 941678-49-5
  • 1312995-182-4
  • MDL No.:
  • MFCD12031592
  • Formula:
  • C17H18N6
  • Molecular:
  • 306.37
  • Form:
  • White powder
  • Storage:
  • -20°C
  • Wish  | Compare  | Referral bonuses
SKU Specification Brand Prices Stock Quantity Cart
BCM006383-1G 1g, Purity:99% BCM $100 4 Add Cart
BCM006383-2G 2g, Purity:99% BCM $192 4 Add Cart
BCM006383-5G 5g, Purity:99% BCM $469 5 Add Cart
BCM006383-10G 10g, Purity:99% BCM $915 2 Add Cart
BCM006383-25G 25g, Purity:99% BCM $2266 4 Add Cart
For more quantities, please contact telephone:0755-85269922,Or send an email to:sales@biochemmall.com

Product Description


Goods Tag

Related Products


Ruxolitinib ( INCB18424 ) is potent, selective JAK1 and JAK2 inhibitors (IC50 at 2.7 and 4.5nM, respectively) with potent antitumor and immunomodulatory activities. Ruxolitinib inhibited IL-6 signaling (IC50=281nM) and proliferation of JAK2V617F+Ba/FChemicalbook3 cells (IC50=127nM). Ruxolitinib also inhibited STAT3 phosphorylation in wild-type JAK2 and JAK2V617F mutants. Clinical application of it can significantly reduce the levels of circulatory inflammatory cytokines. ruxolitinib was effective in rat adjuvant arthritis and multiple rat arthritis models.


Melting Point: 84-89°C


Application status: Ruxolitinib (also known as rucotinib) is a kinase inhibitor used for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, myelofibrosis after polycythemia vera, and myelofibrosis after thrombocythemia essential. ruxolitinib (Jakavi), an oral JAK1 and JAK2 tyrosine kinase inhibitor, was approved in the EU in August 2012 for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, Myelofibrosis after polycythemia vera and myelofibrosis after primary Chemicalbook thrombocythemia. Currently, Rusolitinib Jakavi has been approved by more than 50 countries worldwide, including the European Union, Canada and a number of countries in Asia, Latin America and South America. Novartis licensed the development and commercialization rights for Ruxolitinib outside the United States from Incyte. Both the European Commission and the FDA have granted orphan drug status to Ruxolitinib for the treatment of myelofibrosis. Incyte is already being marketed in the United States under the trade name Jakafi for the treatment of intermediate or high-risk myelofibrosis.


Solubility: Soluble in DMSO (up to 28 mg/ml) or in Ethanol (up to 15 mg/ml with warming).



[Chem Name] Ruxolitinib
[Synonym] (R)-3-(4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile;(betaR)-beta-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile;(3R)-3-(4-(7H-pyrrolo[2,3-d]pyriMidin-4-yl)-1H-pyrazol-1-yl)-3-Chemicalbookcyclopentylpropanenitrile;(3R)-3-cyclopentyl-3-(4-{7H-pyrrolo[2,3-d]pyriMidin-4-yl}-1H-pyrazol-1-yl)propanenitrile;INCB018424(Ruxolitinib);Jakafi;Roxolitinib;β-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyriMidin-4-yl)-(βR)-1H-pyrazole-1-propanenitrile
[CAS No.] 941678-49-5
[EINECS] 1312995-182-4
[MDL No.] MFCD12031592
[Formula] C17H18N6
[Molecular] 306.37
[Form] White powder
[Storage] -20°C

Goods Tag

User Comment(Total0User Comment Num)

  • No comment
Total 0 records, divided into1 pages. First Prev Next Last
Username: Anonymous user
Verification code: captcha